If you've been paying attention to Ottawa's healthcare system over the past two years, you already know what Ozempic has meant for the drug supply: shortages, rationing, patients with Type 2 diabetes struggling to get their medication while the drug simultaneously became a weight-loss phenomenon.
Now a Canadian pharmaceutical company is trying to change that picture, developing a domestically manufactured generic version of semaglutide, the active ingredient in Ozempic and Wegovy.
What the Company Is Doing
The Edmonton-based company is betting that Canadian-made generics can compete on price and availability, particularly as Novo Nordisk's semaglutide patents begin to expire and the global generic market opens up. The pitch isn't just economic nationalism. It's supply chain resilience. A domestic manufacturer can respond to Canadian demand signals in ways that a Danish multinational simply cannot.
The company is targeting regulatory approval through Health Canada's abbreviated new drug submission pathway for generics, a process that compares the new product to the already-approved brand.
Why This Matters for Ottawa
Ottawa's healthcare system, anchored by The Ottawa Hospital, CHEO, Queensway Carleton, and a network of community health centres, has been managing Ozempic-related supply disruptions for over two years. Pharmacists across the city have had to counsel diabetic patients through shortages and substitutions. A reliable domestic supply would directly ease those pressures.
Ottawa is also home to a significant federal biotech and pharma regulatory apparatus. Health Canada's headquarters is here, and the city has a growing life sciences cluster with companies working across drug development, diagnostics, and medical devices.
The Bigger Picture
The pandemic exposed how fragile Canada's dependence on offshore pharmaceutical manufacturing can be. The push for domestic semaglutide production is part of a broader national conversation about building Canadian capacity in medicines that Canadians actually need, not just niche therapeutics, but high-volume, high-demand drugs.
For Ottawa patients, the timeline remains uncertain. Regulatory review takes time. But the signal is encouraging.
Source: CBC Health
